Probiotics Combined With Standard Chemotherapy Plus Targeted Therapy in Patients With Metastatic Colorectal Cancer
Keywords
Abstract
Description
Patients were randomized to either standard therapy (i.e., chemotherapy + targeted therapy) or standard therapy combined with Bifico. We will provide patients with first-line, second-line and third-line treatment with full intervention, including maintenance treatment. The standard treatment regimen, first-line (FOLFOX regimen + cetuximab) : oxaliplatin 85mg/m2 intravenous infusion 2 hours day1 + calcium leucofolate (LV) 400mg/m2 intravenous infusion 2 hours day1 + 5-fluorouracil (5-fu) 400mg/m2 intravenous infusion day 1, and then 1200mg/ (m2·day) ×2 days continuous intravenous infusion + cetuximab 500mg/m2 intravenous infusion over 2 hours day 1, repeat every 2 weeks. First-line treatment 4 to 6 months after the effective disease control or stable but still no radical surgery opportunity, can enter maintenance treatment: 5 - FU + LV (dose with a line), repeat every 2 weeks, or capecitabine oral 2 1250 mg/m2 / day day 1-14 + beacizumab 7.5 mg/kg intravenous day 1, repeat every 3 weeks, or stop the systemic treatment, until a progression, and immediately to the next line treatment; Second-line (FOLFIRI regimen + bevacizumab) : irinotegam 180 mg/m2 iv infusion over 30-90min day 1 + LV 400mg/m2 iv infusion 2 hours day 1 + 5-fu400 mg/m2 iv infusion day 1, then 1200mg/ (m2·day) ×2 days continuous intravenous infusion + bevacizumab 5mg/kg introvenious infusion day 1, repeat every 2 weeks. Third line: fuquinib 160mg oral 1/ day day 1-21, repeat every 28 days, or regofenil 5mg oral 1/ day day 1-21, repeat every 28 days. Bifico 2g oral 3/ day, take the medicine daily.
Dates
| Last Verified: | 09/30/2019 |
| First Submitted: | 10/14/2019 |
| Estimated Enrollment Submitted: | 10/15/2019 |
| First Posted: | 10/17/2019 |
| Last Update Submitted: | 03/15/2020 |
| Last Update Posted: | 03/17/2020 |
| Actual Study Start Date: | 07/24/2020 |
| Estimated Primary Completion Date: | 11/24/2021 |
| Estimated Study Completion Date: | 11/24/2023 |
Condition or disease
Intervention/treatment
Drug: Bifico combined with chemotherapy plus targeted therapy
Drug: chemotherapy plus targeted therapy
Phase
Arm Groups
| Arm | Intervention/treatment |
|---|---|
| Experimental: Bifico combined with chemotherapy plus targeted therapy Bifico combined with chemotherapy plus targeted therapy | Drug: Bifico combined with chemotherapy plus targeted therapy Bifico combined with chemotherapy plus targeted therapy |
| Experimental: chemotherapy plus targeted therapy chemotherapy plus targeted therapy | Drug: chemotherapy plus targeted therapy chemotherapy plus targeted therapy |
Eligibility Criteria
| Ages Eligible for Study | 18 Years To 18 Years |
| Sexes Eligible for Study | All |
| Accepts Healthy Volunteers | Yes |
| Criteria | Inclusion criteria: 1. Age ≥18 years and ≤75 years 2. Histologically and radiologically confirmed colorectal adenocarcinomaImaging and/or pathology confirmed the presence of distal metastases 3. Multidisciplinary team (MDT) identifies unresectable metastatic colorectal cancer (mCRC) 4. RAS and BRAF genes are wild-type 5. The patient had no previous treatment for mCRC, including chemotherapy, surgery, radiotherapy, hepatic artery chemoembolization (TACE) and targeted therapy 6. Hematological function was normal (platelet > 90×109/L; White blood cell > 3×109/L; Neutrophil > 1.5×109/L) 7. Serum bilirubin ≤1.5 times the upper normal value (ULN), transaminase ≤5 times ULN 8. No ascites, normal coagulation function, albumin ≥35g/L 9. Child-push liver function was rated A 10. Serum creatinine is below the upper normal limit (ULN) or the calculated creatinine clearance rate of > 50ml/min (using Cockcroft-Gault formula) 11. ECOG score 2-0 12. Life expectancy > 3 months 13. Sign written informed consent 14. Willing and able to receive follow-up until death or study completion or study termination Exclusion criteria: Patients who meet any of the following criteria will be excluded from the study: 1. Recurrence of primary tumor 2. Severe arterial embolism or ascites 3. A tendency to bleed or clotting disorder 4. Hypertensive crisis or hypertensive encephalopathy 5. Severe uncontrolled systemic complications such as infection or diabetes 6. Clinically serious cardiovascular diseases such as cerebrovascular accident (within 6 months before enrollment), myocardial infarction (within 6 months before enrollment), uncontrolled hypertension after appropriate drug treatment, unstable angina, congestive heart failure (nyha2-4), and arrhythmia requiring drug treatment 7. History of central nervous system disease (e.g. primary brain tumor, epilepsy beyond the control of standard treatment, any brain metastasis or stroke) 8. Other malignancies in the past 5 years (except basal cell carcinoma of skin and/or cervical carcinoma in situ after radical resection) 9. Received any drug under study or treatment with the same type of drug in the last 28 days before the study 10. Any residual toxicity from previous chemotherapy (except hair loss), such as peripheral neuropathy ≥NCI CTC v3.0 standard level 2 11. Is allergic to any of the drugs in the study 12. Pregnant and lactating women 13. Inability or unwillingness to comply with research protocols 14. The presence of any other disease, dysfunction due to metastatic lesions, or a suspected medical condition indicated a possible contraindication to the use of the study drug or a population at high risk for treatment-related complications |
Outcome
Primary Outcome Measures
1. objective response rate [1 year]
